

# Association between serum uric acid/serum creatinine ratios and lung function in the general American population: National Health and Nutrition Examination Survey (NHANES), 2007–2012

Jun Wen,<sup>1</sup> Chengcheng Wei,<sup>2</sup> Mohan Giri,<sup>1</sup> Rongjuan Zhuang,<sup>1</sup> Guo Shuliang<sup>1</sup>

**To cite:** Wen J, Wei C, Giri M, *et al.* Association between serum uric acid/serum creatinine ratios and lung function in the general American population: National Health and Nutrition Examination Survey (NHANES), 2007–2012. *BMJ Open Res* 2023;**10**:e001513. doi:10.1136/bmjresp-2022-001513

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjresp-2022-001513>).

JW, CW and MG contributed equally.

Received 19 October 2022  
Accepted 24 February 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

**Correspondence to**  
Dr Guo Shuliang;  
guoshul666@163.com

## ABSTRACT

**Background** Assessment of lung function is essential for the early screening chronic airway diseases (CADs). Nevertheless, it is still not widely used for early diagnosing CADs in epidemiological or primary care settings. Thus, we used data from the US National Health and Nutrition Examination Survey (NHANES) to discuss the relationship between the serum uric acid/serum creatinine (SUA/SCr) ratio and lung function in general adults to gain the role of SUA/SCr in early assessment of lung function abnormalities.

**Methods** From 2007 to 2012 NHANES, a total of 9569 people were included in our study. Using the regression model, XGBoost algorithm model, generalised linear model and two-piecewise linear regression model, the link between the SUA/SCr ratio and lung function was investigated.

**Results** After correcting for confounding variables, the data revealed that forced vital capacity (FVC) declined by 47.630 and forced expiratory volume in one second (FEV1) decreased by 36.956 for each additional unit of SUA/SCr ratio. However, there was no association between SUA/SCr and FEV1/FVC. In the XGBoost model of FVC, the top five most important were glycohaemoglobin, total bilirubin, SUA/SCr, total cholesterol and aspartate aminotransferase, whereas in FEV1, were glycohaemoglobin, total bilirubin, total cholesterol, SUA/SCr and serum calcium. In addition, we determined the linear and inverse association between SUA/SCr ratio and FVC or FEV1 by constructing a smooth curve.

**Conclusions** In the general American population, the SUA/SCr ratio is inversely linked with FVC and FEV1, but not with FEV1/FVC, according to our research. Future studies should investigate the impact of SUA/SCr on lung function and identify possible mechanisms of action.

## INTRODUCTION

Chronic obstructive pulmonary disease (COPD) and asthma are the two major categories of chronic airway diseases (CADs) that mainly manifests as airflow limitation

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ The outcomes of the published studies suggest that the association between serum uric acid (SUA) and lung function is still controversial. At present, there are no studies on the association between the SUA/serum creatinine (SCr) ratio and lung function parameters in general adults.

## WHAT THIS STUDY ADDS

⇒ This is the first study focusing on the association between SUA/SCr ratios and lung function in the general American population and conducting the stratified analysis by race. SUA/SCr ratio is inversely associated with lung function parameters (forced vital capacity (FVC) and forced expiratory volume in one second (FEV1)).

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ In the general American population, the SUA/SCr ratio is inversely linked with FVC and FEV1, but not with FEV1/FVC. Future studies should investigate the impact of SUA/SCr on lung function and identify possible mechanisms of action.

(AL) with high prevalence worldwide and an increasing trend year by year.<sup>1 2</sup> According to surveys, in Japan, the prevalence of COPD and asthma with AL among patients aged more than 40 years are about 8.9% and 2.0%, respectively.<sup>3 4</sup> And another epidemiological investigation by the Japanese Ministry of Health, Labour and Welfare reported that more than 5 million and 9 million Japanese were estimated to have COPD and asthma, respectively. Nevertheless, the actual number of reported cases of COPD and asthma is 0.2 million and 1.2 million, respectively.<sup>5</sup> This discrepancy indicates that the CADs of reported prevalence may be much lower



than the actual prevalence, and its actual morbidity has been greatly underestimated. Thus, the early screening of CADs is essential before they manifest symptoms and progression. However, patients with early-stage CADs may be either unaware of their condition or reluctant to consult their physician for respiratory symptoms.<sup>6</sup> Assessment for lung function in medical health check-ups or general medical practice is one of the best ways to screen CADs early.<sup>7–9</sup> Nevertheless, in general, only individuals suffering from respiratory symptoms further detect lung function. Besides, lung function assessment is not yet sufficiently widespread within medical health check-ups or primary care settings.<sup>10–11</sup> According to a Chinese study, the rate of lung function assessment in China is low at present. Adults' lung function assessment rate is 9.7%, and that of patients with COPD is only 12%.<sup>12</sup> A simple biomarker used to screen for poor lung function in an epidemiological setting will be very useful for the early assessment, management and treatment of CADs.

Serum uric acid (SUA), the final product of purine degradation, can not only be used to evaluate renal function, but also be considered as a marker reflecting hypoxia status.<sup>13–14</sup> Serum creatinine (SCr) is one of the most common biomarkers to evaluate renal dysfunction.<sup>15</sup> And the SUA/SCr ratio is a standardised SUA index of renal function, which can better reflect the endogenous SUA level.<sup>16–18</sup> Many studies have reported that the SUA/SCr ratio is related to the progression and prognosis of COPD, obstructive sleep apnoea, pulmonary hypertension, chronic respiratory failure and other CADs.<sup>13–19–24</sup> From the perspective of screening, early identification of individuals with the possible risk of abnormal lung function may enable appropriate stratification of prevention and treatment.

According to reported studies, researchers attached more importance to the significance of the SUA/SCr ratio in the progression and prognosis of CADs.<sup>19–24</sup> However, they paid less attention to early screening and identification of CADs. Currently, there are no studies on the relationship between SUA/SCr ratio and lung function parameters in the general adult population. Therefore, this study aimed to use data from the US National Health and Nutrition Examination Survey (NHANES) to discuss the relationship between SUA/SCr ratio and lung function parameters in ordinary adults, and to gain insight into the role of SUA/SCr in early assessment of lung function abnormalities.

## MATERIALS AND METHODS

### Data source

The NHANES, which was conducted by the Centers for Disease Control and Prevention of America, collected information regarding the health and nutritional status of the US population every 2 years. NHANES used a complex, stratified sampling design, which can select representative samples of non-institutionalised civilians. Participants underwent a detailed in-home interview,


physical examination and blood specimen collection at specially equipped mobile examination centres.<sup>25</sup> The Declaration of Helsinki was followed when conducting the study.<sup>26</sup> Written informed consent was obtained from all participants prior to completing the NHANES, and all data were deidentified by the National Center for Health Statistics before being made publicly available.

### Study population

Three 2-year cycle data of the NHANES survey from 2007 to 2012 were integrated into our study. These data included demographic data, medical examination–personal life history, dietary, comorbidities data and laboratory data for the second analysis. When we initially screened in the NHANES database, we found that only lung function data from 2007 to 2012 were available, so we included all participants (n=30 638) in the NHANES from 2007 to 2012. We excluded individuals: (1) aged <18 years old (n=11 823), (2) with at least one of the following factors affecting lung function testing: current chest pain; a physical problem with forceful expiration; use of supplemental oxygen; recent surgery of the eye, chest or abdomen; recent heart attack; stroke; tuberculosis exposure; coughing up of blood (n=743), (3) missing lung function test results data (forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC)) or have low data quality (data with the quality of C, D and F) (n=5663), (4) missing SUA or SCr (n=662), (5) with failing kidneys (n=229), (6) using any drugs that might affect SUA levels, including allopurinol, febuxostat, probenecid, losartan, fenofibrate, pyrazinamide, ethambutol, cyclosporine and thiazide diuretics (n=1251) and missing data about covariates at least one of the following (n=698): body mass index (BMI); physical activity; foods eaten during past 30 days; hypertension history; diabetes history; respiratory diseases history; phosphorus; total bilirubin; total protein; aspartate aminotransferase; glycohaemoglobin. Eventually, a large national representative sample (n=9569) among general American adults was included in this study. The flow chart of the screening process is shown in figure 1.

### Lung function parameters assessment

Lung function was performed using Ohio 822/827 dry-roll volume spirometer and followed the recommendations from the American Thoracic Society (ATS)/European Respiratory Society (ERS).<sup>27</sup> Variables obtained from spirometry and used in this study included FEV1, FVC and the FEV1/FVC ratio. ATS/ERS criteria regarding acceptability and reproducibility of measurements were used to grade spirometry from A to F. Grading A–B fulfilled/exceeded ATS criteria, grading C could be of use while grading D–F was less likely to be useful.<sup>28</sup> It was worth explaining that during the test of FEV1 and FVC, to ensure the accuracy of measurement data, we only used the data with FEV1 and FVC quality



**Figure 1** Flowchart for selecting analysed participants. FEV1, forced expiratory volume in one second; FVC, forced vital capacity; NHANES, National Health and Nutrition Examination Survey; SCr, serum creatinine; SUA, serum uric acid.

grades A and B, not including the data with the quality of C, D and F.

### SCr and SUA measurement

SCr and SUA were analysed on a Beckman UniCel DxC800 Synchron by Collaborative Laboratory Services, LLC. SCr was analysed using the Jaffe rate method. SUA was assessed using a timed endpoint method.

### Other covariates

Other covariates were chosen a priori based on previous studies. Demographic data included gender, age (year), poverty to income ratio, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, others), an educational level (less than high school, high school, more than high school), marital status (married, single, living with a partner). Second, we also included examination data and personal life history data involving BMI ( $\text{kg}/\text{m}^2$ ); physical activity (low, moderate, high); drinking (had at least 12 alcohol drinks/1 year); smoking (smoked at least 100 cigarettes in life); foods eaten during past 30 days (have you eaten shellfish, crab, fish, shrimp or other foods that affect significantly SUA levels during past 30 days); hypertension history, diabetes history and respiratory diseases history. Finally, variables of laboratory data included serum calcium ( $\text{mmol}/\text{L}$ ), phosphorus ( $\text{mmol}/\text{L}$ ), total bilirubin ( $\mu\text{mol}/\text{L}$ ), total protein ( $\text{g}/\text{L}$ ), aspartate aminotransferase ( $\text{U}/\text{L}$ ), alkaline phosphatase ( $\text{U}/\text{L}$ ), total cholesterol ( $\text{mmol}/\text{L}$ ) and glycohaemoglobin (%). More details of variables could

be publicly obtained on the NHANES official website (<https://www.cdc.gov/nchs/nhanes/>).

### Statistical analysis

According to the criteria of the CDC guidelines, we conducted a statistical analysis between the SUA/SCr ratio and lung function parameters (<https://www.cdc.gov/nchs/nhanes/tutorials/default.aspx>). SUA/SCr ratio, lung function parameters and other continuous variables were expressed as the mean $\pm$ SD (normal distribution). The categorical variables were expressed in frequency or percentage. We aimed to discuss the potential correlation of selected participants between the SUA/SCr ratio and lung function parameters. First, we divided the continuous variables of SUA/SCr ratio into four quartile ratios. The weighted  $\chi^2$  was used to calculate the categorical variable, and the weighted linear regression model was used to calculate the continuous variable between the quartile arrays. Second, we constructed three weighted univariate and multivariate linear regression models, including a non-adjusted model, a minimally adjusted model and a fully adjusted model, to figure out the relationship between the SUA/SCr and lung function parameters. Next, based on the fully adjusted model, subgroup analyses were performed to identify the stratified associations between SUA/SCr and lung function parameters using stratified multivariate logistic regression. Furthermore, we constructed the machine learning of the XGBoost algorithm model to predict the relative importance of selected blood biomarkers on the affection of lung function parameters. We performed the XGBoost model to analyse each variable's contribution (gain) to lung function parameters.<sup>29 30</sup> Finally, based on the penalty spline method, we further applied a generalised additive model (GAM) to construct a fully adjusted model with a smooth curve fit to discuss the potential linear relationship between the SUA/SCr and lung function parameters, using the SUA/SCr ratio as a continuous variable in the fully adjusted model. A two-piecewise linear regression model was applied if a non-linear correlation was detected to determine the threshold effect of SUA/SCr on lung function. When the ratio between SUA/SCr and lung function appeared obvious in a smoothed curve, the recursive method automatically calculates the inflection point, where the maximum model likelihood will be used. To prevent the bias caused by missing data, we curated the NHANES database to improve the accuracy of the analysis by using the MICE package for accounting for missing data.<sup>31</sup> We used multiple imputation, based on five replications and the Markov-chain Monte Carlo method in the Multiple imputation of R procedure, to account for missing data on BMI, physical activity, foods eaten during past 30 days, hypertension history, diabetes history, respiratory diseases history, phosphorus, total bilirubin, total protein, aspartate aminotransferase and glycohaemoglobin. Main results of complete data were basically consistent with those of data containing missing





covariates and multiple imputation data (online supplemental table 3). All in all, univariate and multivariate analysis results were based on the calculated dataset as well as Rubin's rules. All kinds of statistical analyses of analysis were performed by R software (V.4.0.2) using the R package. The software EmpowerStats offered significant help in the analysis process, too (<http://www.empowerstats.com>, X&Y Solutions, Boston, Massachusetts, USA). In our study, a  $p$  value  $< 0.05$  was considered statistically significant.

### Patient and public involvement

Patients did not take part in the development, conduct, reporting or dissemination of this study.

## RESULTS

### Characteristics of the participants

The baseline characteristics, which were weighted distribution, were shown in online supplemental table 1, including demographic data, medical examination–personal life history, dietary data, comorbidities data and laboratory data of participants selected from the NHANES (2007–2012) survey. Finally, a total of 9569 participants aged 18–79 years were included in this study. In our study, the average age of the chosen participants was 42.53 years ( $\pm 16.17$ ), and non-Hispanic whites were the main participants. Then, we divided different SUA/SCr ratios into four quartiles (Q1–Q4). We found the distribution of smoking situation, food of affecting SUA intake during past 30 days, and serum calcium in four quartiles indicated no statistical difference ( $p$  values  $> 0.05$ ), but other variates showed statistical difference ( $p$  values  $< 0.05$ ). Compared with participants with a lower SUA/SCr ratio, the participants with higher SUA/SCr were more likely to be females, young, non-Hispanic whites, married, less physical activity, with hypertension history, patients with diabetes history and without respiratory disease. Besides, participants with higher SUA/SCr had lower poverty to income ratio, higher BMI, higher education and more alcohol.

### The correlation between SUA/SCr ratio and lung function parameters

We applied three weighted univariate and multivariate linear regression models to assess the correlation of SUA/SCr with lung function parameters. As shown in table 1, we found in the non-adjusted model, which adjusted for none, the SUA/SCr showed a positive association with FEV1/FVC, and FEV1/FVC increased by 0.003 for each additional unit of SUA/SCr with  $p$  for trend less than 0.05. However, the SUA/SCr showed a negative association with FVC, and FVC decreased by 39.972 for each additional unit of SUA/SCr with  $p$  for trend less than 0.05. In the fully adjusted model, which adjusted for gender, age, race/ethnicity, education level, poverty income ratio, marital status, physical activity, BMI, hypertension history,

diabetes history, respiratory disease history, had at least 12 alcohol drinks/1 year, smoked at least 100 cigarettes in life, foods of affecting SUA eaten during past 30 days, serum calcium, phosphorus, total bilirubin, total protein, aspartate aminotransferase, alkaline phosphatase, total cholesterol and glycohaemoglobin, there was a positive association between SUA/SCr and FEV1/FVC without statistical significance. On the other hand, the SUA/SCr showed a negative association with FVC and FEV1 with statistical significance, FVC decreased by 47.630, and FEV1 decreased by 36.956 for each additional unit of SUA/SCr with  $p$  for trend less than 0.05.

### Stratified associations between SUA/SCr ratio with lung function parameters

As shown in online supplemental table 2, based on the fully adjusted model, we further analysed stratified associations between SUA/SCr and lung function parameters in a specific subgroup by gender, age, race, education level, poverty income ratio, marital status, physical activity, BMI, respiratory disease history, smoking status, drinking status and foods of affecting SUA eaten during past 30 days. On all selected subgroup analyses, SUA/SCr had a negative relationship with FVC among the remaining subgroups, except for the subgroup of age  $< 40$ , other Hispanic, non-Hispanic black, other race, single or living with a partner status, high physical activity and with hypertension history. And, SUA/SCr had a negative relationship with FEV1 among the remaining subgroups, except for the subgroup of age  $< 40$  or  $\geq 60$ , Mexican American, other Hispanic, non-Hispanic black, other race, living with a partner, high physical activity and with hypertension history. However, the correlations between SUA/SCr and FEV1/FVC were not statistically significant among all subgroups. Moreover, we detected a significant difference by  $p$  for the interaction analyses. Variables of age and SUA/SCr may have an interaction effect associated with FVC ( $p$  for interaction  $< 0.0001$ ).

### Using machine learning of the XGBoost algorithm model to explore the selected blood biomarkers' relative importance

To identify which blood markers affected lung function parameters more, we constructed the XGBoost Algorithm model machine learning to determine the relative importance among all selected blood markers. According to the results of each variable's contribution by the XGBoost model of FVC, glycohaemoglobin, total bilirubin, SUA/SCr, total cholesterol and aspartate aminotransferase were the top five most important variables of selected variables (figure 2A). But in the XGBoost model of FEV1, it could be seen that the top five important variables were glycohaemoglobin, total bilirubin, total cholesterol, SUA/SCr and serum calcium, respectively (figure 2B). Ultimately, SUA/SCr, as the relatively significant variable, was applied to constructing smooth curve models in our study.


**Table 1** Multivariate weighted regression model analysis reveals the associations between SUA/SCr and lung function parameters

	Non-adjusted model	Minimally adjusted model	Fully adjusted model
	$\beta$ (95% CI) P value	$\beta$ (95% CI) P value	$\beta$ (95% CI) P value
<b>FVC</b>			
SUA/SCr	-39.972 (-73.515 to -6.429) 0.0237	-72.676 (-92.046 to -53.306) <0.0001	-47.630 (-63.499 to -31.761) <0.0001
SUA/SCr quartile categories			
Q1	Reference	Reference	Reference
Q2	77.741 (-5.653 to 161.135) 0.0742	-79.625 (-127.611 to -31.639) 0.0023	-66.127 (-113.530 to -18.724) 0.0136
Q3	71.472 (-13.480 to 156.423) 0.1060	-120.115 (-173.522 to -66.708) 0.0001	-87.273 (-138.182 to -36.365) 0.0035
Q4	-83.842 (-182.899 to 15.215) 0.1039	-192.008 (-247.354 to -136.662) <0.0001	-123.615 (-172.507 to -74.723) 0.0001
P for trend	0.1135	<0.0001	<0.0001
<b>FEV1</b>			
SUA/SCr	-17.377 (-46.297 to 11.544) 0.2447	-51.980 (-69.899 to -34.060) <0.0001	-36.956 (-52.375 to -21.537) 0.0001
SUA/SCr quartile categories			
Q1	Reference	Reference	Reference
Q2	64.750 (-1.912 to 131.411) 0.0632	-61.515 (-100.261 to -22.768) 0.0034	-54.074 (-93.022 to -15.125) 0.0140
Q3	55.559 (-19.283 to 130.401) 0.1525	-93.760 (-138.237 to -49.282) 0.0002	-75.024 (-117.771 to -32.278) 0.0029
Q4	-34.360 (-117.268 to 48.548) 0.4208	-141.514 (-192.237 to -90.791) <0.0001	-99.934 (-145.484 to -54.384) 0.0004
P for trend	0.4315	<0.0001	0.0002
<b>FEV1/FVC</b>			
SUA/SCr	0.003 (0.001 to 0.006) 0.0064	0.001 (-0.001 to 0.003) 0.2161	-0.000 (-0.002 to 0.002) 0.9469
SUA/SCr quartile categories			
Q1	Reference	Reference	Reference
Q2	0.001 (-0.004 to 0.006) 0.7578	-0.000 (-0.005 to 0.005) 0.9865	-0.001 (-0.005 to 0.004) 0.7059
Q3	0.001 (-0.005 to 0.006) 0.8214	0.001 (-0.004 to 0.006) 0.7602	-0.001 (-0.006 to 0.004) 0.7037
Q4	0.008 (0.000 to 0.015) 0.0422	0.002 (-0.003 to 0.008) 0.4559	-0.001 (-0.006 to 0.005) 0.7503
P for trend	0.0599	0.4324	0.7492
Non-adjusted model adjusted for none.			
Minimally adjusted model adjusts for gender, age and race/ethnicity.			
Fully adjusted model adjusts for gender, age, race/ethnicity, education level, poverty income ratio, marital status, physical activity, body mass index, hypertension history, diabetes history, respiratory disease history had at least 12 alcohol drinks/year, smoked at least 100 cigarettes in life, foods of affecting SUA eaten during past 30 days, serum calcium, phosphorus, total bilirubin, total protein, aspartate aminotransferase, alkaline phosphatase, total cholesterol and glycohaemoglobin.			
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; SCr, serum creatinine; SUA, serum uric acid.			

### Using GAM to explore the possible linear relationship between SUA/SCr ratio and lung function parameters

To verify the reliability and stability of multivariate regression analysis results, based on the fully adjusted model, we used GAM to explore the possible linear relationship

between SUA/SCr and lung function parameters. The relationship between SUA/SCr and FVE or FEV1 was approximately linear and inversely (figure 3A,B). In addition, we used the two-piecewise linear regression model to further confirm the linear relationship of SUA/SCr




**Figure 2** XGBoost model revealed the relative importance of selected blood markers on the lung function parameters ((A) forced vital capacity, (B) forced expiratory volume in one second) and the corresponding variable importance score. The x-axis showed the importance score, the relative number of a variable used to distribute the data; the y-axis indicated the selected blood markers. ALP, alkaline phosphatase; AST, aspartate aminotransferase; Ca++, Serum calcium; HbA1c, glycohaemoglobin; P, phosphorus; SUA/SCr, serum uric acid/creatinine; TBIL, total bilirubin; TC, total cholesterol; TP, total protein.

with lung function parameters (table 2). The log likelihood ratio test showed that p was more than 0.05, indicating no significant difference between model 1 (one-line model) and model 2 (segmented regression model). Therefore, it was more suitable to use the one-line model, and the inflection point was not statistically significant. All previous results indicated a negative and linear correlation between SUA/SCr ratio and FVC or FEV1.

## DISCUSSION

As far as we know, our study is the first study to explore the relationship between SUA/SCr and lung function parameters among general American adults and is also one of the most extensive cross-sectional studies to explore this relationship. Based on NHANES data from 2007 to 2012, we found that the SUA/SCr was inversely associated



**Figure 3** Based on the fully adjusted model, the relationship between serum uric acid/serum creatinine (SUA/SCr) ratio and lung function parameters ((A) forced vital capacity (FVC), (B) forced expiratory volume in one second (FEV1)). The solid red line represented the smooth fitting curve between variables, and the blue band represented the 95% CI of the fitting.

with lung function parameters (FVC,  $\beta=-47.630$ ; FEV1,  $\beta=-36.956$ ) after adjusting for the demographic data, examination data, personal life history data, comorbidities data and laboratory data. To verify the accuracy and stability of this association, we conducted stratified analyses. The results indicated, among all selected subgroup analyses, SUA/SCr had a negative relationship with FVC among the remaining subgroups, except for the subgroup of age<40, other Hispanic, non-Hispanic black, other race, single or living with a partner status, high physical activity and with hypertension history; SUA/SCr had a negative relationship with FEV1 among the remaining subgroups, except for the subgroup of age<40 or  $\geq 60$ , Mexican American, other Hispanic, non-Hispanic black, other race, living with a partner, high physical activity and with hypertension history. However, the correlations between SUA/SCr and FEV1/FVC were not statistically significant. In addition, we also constructed the machine learning of the XGBoost Algorithm model to determine the relative importance of selected blood biomarkers associated with lung function parameters, and SUA/SCr was the relatively more significant biomarker. SUA/SCr, as the relatively significant biomarker, was used to construct smooth curve models to further verify the robustness of the result. Finally, our study showed that based on the fully adjusted model, FVC decreased by 47.630 mL and FEV1 decreased by 36.956 mL for each additional unit of SUA/SCr, with statistical significance, but the correlation between SUA/SCr and FEV1/FVC was not statistically significant.

SUA is the final product of the metabolic conversion of both exogenous purines and endogenous purines.<sup>32</sup> Diet (intake of purines), drugs (allopurinol, probenecid, thiazide diuretics and so on), drinking, smoking, exercise, BMI, renal dysfunction, hypertension history and diabetes history also affect SUA levels.<sup>32-38</sup> Thus, we should take these factors into careful consideration when assessing the correlation between SUA/SCr and pulmonary function. Since UA elimination mainly occurred in urine,<sup>39</sup> and various systemic diseases might affect SUA levels, we analysed the data by correcting the SUA for the SUA level. Interestingly, this study found that SUA/SCr ratio was inversely associated with lung function parameters (FVC and FEV1).

The results of our study are similar to those of one Japanese study and two Korean studies. The Japanese study was the community-based annual health check for the general population aged more than 40 years in Japan, which reported that lung function parameters (FEV1% predicted and FVC% predicted) were inversely associated with SUA in females.<sup>40</sup> And two other Korean studies indicated that SUA levels were inversely correlated with FVC or FEV1 among the female general population, and there was no significant correlation between SUA and FEV1/FVC ratio.<sup>41 42</sup> In addition, another retrospective cohort study involving 19237 participants reported that accelerated FVC and FEV1/FVC ratio declines were observed in non-smoking individuals with increased SUA levels using

**Table 2** Threshold effect analysis of between SUA/SCr and lung function parameters using the two-piecewise linear regression model

	FVC	FEV1
	$\beta$ (95% CI) P value	$\beta$ (95% CI) P value
Model I		
Linear effect	-47.865 (-61.583 to -34.146) <0.0001	-37.225 (-48.482 to -25.969) <0.0001
Model II		
Inflection point(K)	4.734	4.069
SUA/SCr<K	-62.705 (-85.131 to -40.278) <0.0001	-57.511 (-84.517 to -30.506) <0.0001
SUA/SCr>K	-28.839 (-55.401 to -2.276) 0.0334	-27.649 (-43.804 to -11.494) 0.0008
Log likelihood ratio	0.101	0.105

The model I and II all adjusted for gender, age, race/ethnicity, education level, poverty income ratio, marital status, physical activity, body mass index, hypertension history, diabetes history, respiratory disease history had at least 12 alcohol drinks/year, smoked at least 100 cigarettes in life, foods of affecting SUA eaten during past 30 days, serum calcium, phosphorus, total bilirubin, total protein, aspartate aminotransferase, alkaline phosphatase, total cholesterol and glycohaemoglobin.  
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; SCr, serum creatinine; SUA, serum uric acid.

linear mixed models.<sup>43</sup> Nevertheless, our study was inconsistent with another Korean study, which demonstrated there was a significant positive relationship between SUA and lung function parameters, among 69928 participants recruited from Kangbuk Samsung Hospital Health Screening Center, Seoul, Korea.<sup>44</sup> The Korean study excluded the participants with a self-reported history of underlying diseases, including hypertension history, diabetes history, respiratory diseases history and so on. However, our study included a population with underlying diseases of hypertension history, diabetes history and respiratory diseases history. On account of the heterogeneity of reported researches, such as in terms of demographic data, examination data, personal life history data, comorbidities data and statistical analysis and so on, it was hard to determine the correlation between SUA and lung function, which might explain the difference in reported epidemiological researches. And we conducted relatively comprehensive stratified analysis (including demographic data, examination data, personal life history data and comorbidities data) to confirm the accuracy and stability of the results. Correspondingly, our study demonstrated the corrected SUA (SUA/SCr) was inversely associated with FVC and FEV1 in the general American population, but not associated with FEV1/FVC. Therefore, we suggested that our study results are more credible than those of previous studies.

According to previous studies, there is still controversy regarding UA's role in inflammation.<sup>45</sup> As an essential upper airway antioxidant, UA can eliminate reactive oxygen species (ROS) and get rid of peroxy-nitrite.<sup>46</sup> UA, existing at high concentrations in the epithelial fluid of the human respiratory tract, is a significant first-line defence against ROS.<sup>47 48</sup> On the other hand, UA serves as a proinflammatory molecule in endothelial.<sup>49 50</sup> Some reported studies demonstrated that SUA had been suggested to serve as a biomarker of respiratory diseases such as asthma,<sup>22 51</sup> COPD,<sup>23 24 52 53</sup> lung cancer,<sup>54</sup>

obstructive sleep apnoea,<sup>55</sup> pulmonary hypertension<sup>56</sup> and chronic respiratory failure.<sup>13</sup>

The uric acid level reflects the degrees of systemic inflammation and tissue hypoxia. Several possible explanations exist for the negative association between SUA levels and lung function. First, the production of UA is induced by hypoxia in participants with impaired lung function. Elsayed *et al* demonstrated that experimentally induced hypoxia resulted in substantially higher UA concentrations in lung perfusate and lung tissues of animals, as compared with either normoxia or hyperoxia.<sup>57</sup> Second, prolonged hypoxaemia may induce pulmonary hypertension, which further results in the elevation of SUA levels. Loss of pulmonary vasculature and hypoxic vascular contraction may result in pulmonary hypertension among patients with COPD. Previous studies demonstrated the correlation between pulmonary arterial pressure and SUA levels.<sup>58 59</sup> The alteration of haemodynamics may result in an elevation of SUA. Next, systemic UA levels are related to inflammation and oxidative stress in vivo, which induces lung function damage. Bartziokas *et al* demonstrated that SUA levels might rise due to lung tissue damage among patients with COPD with high levels of lung oxidative stress and inflammation.<sup>24</sup> Fourth, elevated levels of UA contribute to systemic inflammation, which eventually impairs lung function. A large number of reported studies indicated that SUA was positively associated with inflammatory markers such as leukocytes, C reactive protein and interleukin 6.<sup>60 61</sup> Subsequently, activated inflammatory markers lead to damage to vascular endothelial cells. Alveolar septal cell apoptosis and emphysema are linked to pulmonary endothelial dysfunction. Thus, pulmonary endothelial dysfunction associated with hyperuricaemia may be related to the impairment of pulmonary function in the general population.<sup>62</sup>

As is known to us, the assessment of lung function is essential for the early screening of CADs. Even though





lung function has become more accessible in recent years, it is still not widely used for diagnosing CADs in the epidemiological or primary care settings.<sup>10,11</sup> Further campaigns are required to promote the expansion of the assessment of lung function. If a simple marker is used for screening abnormal lung function, it will be of great significance for the early identification, management, and treatment of CADs. Our study indicated that SUA/SCr was inversely associated with FVC and FEV1, but not associated with FEV1/FVC in the general population. In the future, more prospective researches should be conducted to explore the role of SUA/SCr in lung function.

Compared with previously published articles, our study has several advantages. First, our study included a large sample with a total of 9569 participants. Second, considering that other covariates may impact the results, we conducted roundly stratified analysis, which may help to find possible susceptible populations and verify the stability of the results. Next, we used the machine learning of the XGBoost Algorithm model to assess selected blood biomarkers' contribution to lung function. Finally, we constructed a smooth curve based on the fully adjusted model to explore the possible linear relationship between SUA/SCr ratio and lung function parameters.

Nevertheless, some limitations in interpreting our results need to be taken into account. First, since the NHANES database is a cross-sectional survey, we are unable to distinguish causality in our study. Thus, more prospective cohort studies are still required to verify the causality. Second, our study did not exclude participants with respiratory diseases and other comorbidities (such as hypertension and diabetes mellitus). Third, similar to other cross-sectional studies, there are still other potentially confounding factors that are not considered, though we have adjusted for many confounding factors. At last, our investigation is based on the NHANES database, which applies to the American population so generalisability is geographically restricted. More comprehensive investigations are required to determine the relationship between SUA and lung function parameter (specially FEV1/FVC) in the future.

## CONCLUSIONS

In conclusion, our study indicates SUA/SCr ratio is inversely associated with FVC and FEV1 in the general American population, but not associated with FEV1/FVC. In the future, more prospective researches should be conducted to explore the role of SUA/SCr in lung function and to determine potential mechanisms of action.

## Author affiliations

<sup>1</sup>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China

<sup>2</sup>Department of Urology, Huazhong University of Science and Technology, Wuhan, China

**Contributors** JW carried out the study design, data extraction and statistical analysis and drafted the manuscript. CW conducted data extraction and statistical analysis and drafted the manuscript. MG carried out the study design and revision of the paper. RZ carried out the study design. GS participated in the study design and revision of the paper. GS is the guarantor of this study. All authors read and approved the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Data may be obtained from a third party and are not publicly available.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## REFERENCES

- Singh D, Agusti A, Anzueto A, *et al*. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the gold science Committee report 2019. *Eur Respir J* 2019;53:1900164.
- Reddel HK, Bacharier LB, Bateman ED, *et al*. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. *Am J Respir Crit Care Med* 2022;205:17–35.
- Matsumoto K, Seki N, Fukuyama S, *et al*. Prevalence of asthma with airflow limitation, COPD, and COPD with variable airflow limitation in older subjects in a general Japanese population: the hisayama study. *Respir Invest* 2015;53:22–9.
- Fukuchi Y, Nishimura M, Ichinose M, *et al*. Copd in Japan: the nippon COPD epidemiology study. *Respirology* 2004;9:458–65.
- Fukuhara A, Saito J, Sato S, *et al*. The association between risk of airflow limitation and serum uric acid measured at medical health check-ups. *Int J Chron Obstruct Pulmon Dis* 2017;12:1213–9.
- van den Boom G, van Schayck CP, van Möllen MP, *et al*. Active detection of chronic obstructive pulmonary disease and asthma in the general population. results and economic consequences of the DIMCA program. *Am J Respir Crit Care Med* 1998;158:1730–8.
- Chang JH, Lee JH, Kim M, *et al*. Determinants of respiratory symptom development in patients with chronic airflow obstruction. *Respiratory Medicine* 2006;100:2170–6.
- Buffels J, Degryse J, Heyrman J, *et al*. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO study. *Chest* 2004;125:1394–9.
- Bridevaux P-O, Probst-Hensch NM, Schindler C, *et al*. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. *Eur Respir J* 2010;36:1259–69.
- Han MK, Kim MG, Mardon R, *et al*. Spirometry utilization for COPD: how do we measure up? *Chest* 2007;132:403–9.
- Arne M, Lisspers K, Ställberg B, *et al*. How often is diagnosis of COPD confirmed with spirometry? *Respir Med* 2010;104:550–6.
- Wang C, Xu J, Yang L, *et al*. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the china pulmonary health [CPH] study): a national cross-sectional study. *Lancet* 2018;391:1706–17.
- Kadowaki T, Hamada H, Yokoyama A, *et al*. Significance of serum uric acid in patients with chronic respiratory failure treated with non-invasive positive pressure ventilation. *Intern Med* 2007;46:691–7.



- 14 Grassi D, Ferri L, Desideri G, *et al.* Chronic hyperuricemia, uric acid deposit and cardiovascular risk. *Curr Pharm Des* 2013;19:2432–8.
- 15 Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. *Clin Chem* 1992;38:1933–53.
- 16 Tao J, Shen X, Li J, *et al.* Serum uric acid to creatinine ratio and metabolic syndrome in postmenopausal Chinese women. *Medicine (Baltimore)* 2020;99:e19959.
- 17 Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. *Annu Rev Med* 1988;39:465–90.
- 18 Gu L, Huang L, Wu H, *et al.* Serum uric acid to creatinine ratio: a predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function. *Diab Vasc Dis Res* 2017;14:221–5.
- 19 Savale L, Akagi S, Tu L, *et al.* Serum and pulmonary uric acid in pulmonary arterial hypertension. *Eur Respir J* 2021;58:2000332.
- 20 Sato N, Kurashima K, Ubukata M, *et al.* Prognostic significance of serum uric acid in patients with chronic obstructive pulmonary disease receiving home oxygen therapy. *Nihon Kokyuki Gakkai Zasshi* 2003;41:74–80.
- 21 Saito H, Nishimura M, Shibuya E, *et al.* Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine. *Chest* 2002;122:1686–94.
- 22 Li L, Wan C, Wen F. An unexpected role for serum uric acid as a biomarker for severity of asthma exacerbation. *Asian Pac J Allergy Immunol* 2014;32:93–9.
- 23 Garcia-Pachon E, Padilla-Navas I, Shum C. Serum uric acid to creatinine ratio in patients with chronic obstructive pulmonary disease. *Lung* 2007;185:21–4.
- 24 Bartzioikas K, Papaioannou AI, Loukides S, *et al.* Serum uric acid as a predictor of mortality and future exacerbations of COPD. *Eur Respir J* 2014;43:43–53.
- 25 Zou Q, Wang H, Su C, *et al.* Longitudinal association between physical activity and blood pressure, risk of hypertension among Chinese adults: China health and nutrition survey 1991–2015. *Eur J Clin Nutr* 2021;75:274–82.
- 26 World Medical Association. World Medical association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013;310:2191–4.
- 27 Standardization of spirometry, 1994 update. American thoracic society. *Am J Respir Crit Care Med* 1995;152:1107–36.
- 28 Graham BL, Brusasco V, Burgos F, *et al.* Executive summary: 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J* 2017;49:16E0016.
- 29 Zhang Z, Ho KM, Hong Y. Machine learning for the prediction of volume responsiveness in patients with oliguric acute kidney injury in critical care. *Crit Care* 2019;23:112.
- 30 Livne M, Boldsen JK, Mikkelsen IK, *et al.* Boosted tree model reforms multimodal magnetic resonance imaging infarct prediction in acute stroke. *Stroke* 2018;49:912–8.
- 31 Hsu CH, Yu M. Cox regression analysis with missing covariates via nonparametric multiple imputation. *Stat Methods Med Res* 2019;28:1676–88.
- 32 Kang DH, Ha SK. Uric acid puzzle: dual role as anti-oxidant and pro-oxidant. *Electrolyte Blood Press* 2014;12:1–6.
- 33 Rathmann W, Haastert B, Icks A, *et al.* Ten-Year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the cardia study. *Eur J Epidemiol* 2007;22:439–45.
- 34 Nicks ME, O'Brien MM, Bowler RP. Plasma antioxidants are associated with impaired lung function and COPD exacerbations in smokers. *COPD* 2011;8:264–9.
- 35 Nan H, Qiao Q, Söderberg S, *et al.* Serum uric acid and components of the metabolic syndrome in non-diabetic populations in mauritian Indians and creoles and in Chinese in Qingdao, China. *Metab Syndr Relat Disord* 2008;6:47–57.
- 36 Kutzing MK, Firestein BL. Altered uric acid levels and disease states. *J Pharmacol Exp Ther* 2008;324:1–7.
- 37 Conen D, Wietlisbach V, Bovet P, *et al.* Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. *BMC Public Health* 2004;4:9.
- 38 Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the third National health and nutrition examination survey. *Arthritis Rheum* 2004;51:1023–9.
- 39 Marangella M. Uric acid elimination in the urine. Pathophysiological implications. *Contrib Nephrol* 2005;147:132–48.
- 40 Aida Y, Shibata Y, Osaka D, *et al.* The relationship between serum uric acid and spirometric values in participants in a health check: the takahata study. *Int J Med Sci* 2011;8:470–8.
- 41 Jeong H, Baek S-Y, Kim S-W, *et al.* Gender-Specific association of serum uric acid and pulmonary function: data from the Korea National health and nutrition examination survey. *Medicina (Kaunas)* 2021;57:953.
- 42 Hong JW, Noh JH, Kim DJ. Association between serum uric acid and spirometric pulmonary function in Korean adults: the 2016 Korea national health and nutrition examination survey. *PLoS One* 2020;15:e0240987.
- 43 Ahn KM, Lee SY, Lee SH, *et al.* Lung function decline is associated with serum uric acid in Korean health screening individuals. *Sci Rep* 2021;11:10183.
- 44 Song JU, Hwang J, Ahn JK. Serum uric acid is positively associated with pulmonary function in Korean health screening examinees. *Mod Rheumatol* 2017;27:1057–65.
- 45 El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: a review. *J Adv Res* 2017;8:487–93.
- 46 Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. *Nucleosides Nucleotides Nucleic Acids* 2008;27:608–19.
- 47 van der Vliet A, O'Neill CA, Cross CE, *et al.* Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids. *Am J Physiol* 1999;276:L289–96.
- 48 Housley DG, Mudway I, Kelly FJ, *et al.* Depletion of urate in human nasal lavage following in vitro ozone exposure. *Int J Biochem Cell Biol* 1995;27:1153–9.
- 49 Kirschvink N, Fiévez L, Bureau F, *et al.* Adaptation to multiday ozone exposure is associated with a sustained increase of bronchoalveolar uric acid. *Free Radic Res* 2002;36:23–32.
- 50 Becker BF, Reinholz N, Leipert B, *et al.* Role of uric acid as an endogenous physical radical scavenger and antioxidant. *Chest* 1991;100:176S–181S.
- 51 Garcia-Larsen V, Chinn S, Rodrigo R, *et al.* Relationship between oxidative stress-related biomarkers and antioxidant status with asthma and atopy in young adults: a population-based study. *Clin Exp Allergy* 2009;39:379–86.
- 52 Yang H, Wang Z, Xiao S, *et al.* Association between serum uric acid and lung function in people with and without chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2022;17:1069–80.
- 53 Durmus Kocak N, Sasak G, Aka Akturk U, *et al.* Serum uric acid levels and uric acid/creatinine ratios in stable chronic obstructive pulmonary disease (COPD) patients: are these parameters efficient predictors of patients at risk for exacerbation and/or severity of disease? *Med Sci Monit* 2016;22:4169–76.
- 54 Horsfall LJ, Nazareth I, Petersen I. Serum uric acid and the risk of respiratory disease: a population-based cohort study. *Thorax* 2014;69:1021–6.
- 55 Wan Y, Zheng Y, Niu H, *et al.* Uric acid levels in obstructive sleep apnea patients with atrial fibrillation. *Arch Med Res* 2014;45:132–7.
- 56 Simpson CE, Damico RL, Hummers L, *et al.* Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. *Pulm Circ* 2019;9:2045894019859477.
- 57 Elsayed NM, Nakashima JM, Postlethwait EM. Measurement of uric acid as a marker of oxygen tension in the lung. *Arch Biochem Biophys* 1993;302:228–32.
- 58 Zhang CY, Ma LL, Wang LX. Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension. *Exp Clin Cardiol* 2013;18:e37–9.
- 59 Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, *et al.* Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. *Eur J Heart Fail* 2007;9:518–24.
- 60 Ruggiero C, Cherubini A, Ble A, *et al.* Uric acid and inflammatory markers. *Eur Heart J* 2006;27:1174–81.
- 61 Martinon F, Pétrilli V, Mayor A, *et al.* Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* 2006;440:237–41.
- 62 Kahnert K, Alter P, Welte T, *et al.* Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. *Respir Res* 2018;19:110.

Supplementary Table 1. Baseline characteristics of the selected participants.

SUA/SCr ratio	Q1(0.320-3.607)	Q2(3.608-4.231)	Q3(4.232-4.958)	Q4(4.959-13.127)	P value
N	2392	2389	2394	2394	
Demographic variables					
Gender(%)					<0.0001
Male	42.879	51.924	53.734	48.413	
Female	57.121	48.076	46.266	51.587	
Age,mean±SD(years)	43.042 ± 15.366	42.094 ± 15.025	42.298 ± 15.026	41.185 ± 14.991	0.00051
Race/ethnicity(%)					<0.0001
Mexican American	5.125	7.21	8.735	14.112	
Other Hispanic	4.691	5.68	4.68	6.827	
Non-Hispanic White	72.052	71.441	72.476	64.228	
Non-Hispanic Black	13.623	10.057	7.489	6.604	
Other Race	4.509	5.613	6.62	8.229	
Poverty to income ratio, mean±SD	3.168 ± 1.633	3.127 ± 1.603	3.085 ± 1.609	2.856 ± 1.619	<0.0001
Education(%)					<0.0001
Less than high school	12.825	14.052	16.041	19.846	
High school	21.008	20.38	21.408	23.322	
More than high school	66.167	65.568	62.552	56.831	
Marital status (%)					0.00264
Married	58.711	54.312	57.083	54.01	
Single	34.107	36.643	34.744	36.151	
Living with a partner	7.182	9.046	8.173	9.839	
Medical examination and personal life history					
BMI,mean±SD	25.799 ± 4.826	27.349 ± 5.712	28.904 ± 6.373	31.051 ± 7.236	<0.0001
Physical activity(%)					<0.0001
Low	36.058	40.052	41.056	47.132	
Moderate	27.537	27.299	30.103	28.782	
High	36.405	32.649	28.84	24.086	
Had at least 12 alcohol drinks/1 year(%)					0.00585
Yes	80.02	82.383	81.832	78.853	
No	19.98	17.617	18.168	21.147	

Smoked at least 100 cigarettes in life(%)					0.05675
Yes	42.686	44.339	45.725	46.237	
No	57.314	55.661	54.275	53.763	
Foods of affecting SUA eaten during past 30 days					0.47583
Yes	72.639	72.325	71.15	70.941	
No	27.361	27.675	28.85	29.059	
<hr/>					
Comorbidities (%)					
Hypertension history					<0.00001
Yes	15.559	16.331	20.304	24.779	
No	84.441	83.669	79.696	75.221	
Diabetes history					<0.00001
Yes	4.55	3.606	4.679	7.168	
No	95.45	96.394	95.321	92.832	
Respiratory diseases history					0.00075
Yes	14.809	16.458	17.213	19.263	
No	85.191	83.542	82.787	80.737	
<hr/>					
Variables of laboratory data					
Serum phosphorus,mean±SD(mmol/L)	1.224 ± 0.184	1.204 ± 0.179	1.217 ± 0.177	1.218 ± 0.179	0.00106
Serum calcium,mean±SD(mmol/L)	2.355 ± 0.087	2.354 ± 0.087	2.353 ± 0.086	2.352 ± 0.088	0.76306
Total bilirubin,mean±SD(umol/L)	12.497 ± 5.147	13.151 ± 4.880	13.500 ± 5.537	12.939 ± 4.980	<0.00001
Total protein,mean±SD(g/L)	70.481 ± 4.322	71.169 ± 4.398	71.252 ± 4.387	71.949 ± 4.583	<0.00001
Aspartate aminotransferase,mean±SD(U/L)	24.146 ± 10.924	25.098 ± 13.032	25.829 ± 17.068	27.588 ± 15.583	<0.00001
Alkaline phosphatase,mean±SD(U/L)	61.488 ± 18.996	64.894 ± 25.117	67.035 ± 19.746	69.662 ± 21.447	<0.00001
Glycohemoglobin,mean±SD(%)	5.481 ± 0.817	5.447 ± 0.754	5.491 ± 0.692	5.579 ± 0.874	<0.00001
Total cholesterol,mean±SD(mm	4.964 ± 1.010	5.006 ± 1.034	5.090 ± 1.057	5.210 ± 1.060	<0.00001



ol/L)

Lung function parameters					
FVC, mean±SD(ml)	4227.360 ± 1016.580	4305.980 ± 1028.962	4298.983 ± 1092.570	4143.118 ± 1114.054	<0.000 01
FEV1, mean±SD(ml)	3309.628 ± 843.076	3374.720 ± 860.310	3365.087 ± 901.047	3274.566 ± 920.114	0.0001 5
FEV1/FVC, mean±SD	0.783 ± 0.077	0.784 ± 0.080	0.784 ± 0.080	0.791 ± 0.076	0.0023 3

Note: Q1–Q4: Grouped by quartile according to SUA/SCr ratios. Our data included demographic data, medical examination–personal life history, dietary, comorbidities data, and laboratory data for the second analysis.

Supplementary Table 2. The stratified analysis of the association between SUA/SCr and lung function parameters.

	FVC	FEV1	FEV1/FVC
	β (95% CI) P value	β (95% CI) P value	β (95% CI) P value
<b>Gender</b>			
Male	-45.312 (-70.414, -20.210) 0.0022	-35.355 (-59.381, -11.328) 0.0095	-0.001 (-0.003, 0.001) 0.3039
Female	-49.486 (-68.777, -30.195) 0.0001	-38.239 (-55.416, -21.062) 0.0003	0.001 (-0.002, 0.003) 0.4871
P for interaction	0.791	0.8353	0.1681
<b>Age</b>			
<40	-15.144 (-35.635, 5.347) 0.1657	-9.921 (-26.141, 6.298) 0.2470	0.000 (-0.002, 0.003) 0.7175
40–60	-63.820 (-93.218, -34.421) 0.0005	-46.045 (-75.448, -16.643) 0.0069	0.001 (-0.002, 0.005) 0.4725
>=60	-45.672 (-84.043, -7.302) 0.0322	-24.049 (-58.495, 10.398) 0.1890	0.002 (-0.003, 0.007) 0.4898
P for interaction	0.0141	0.0761	0.8435
<b>Race/ethnicity</b>			
Mexican American	-36.524 (-68.101, -4.947) 0.0376	-21.486 (-46.161, 3.189) 0.1072	0.002 (-0.001, 0.004) 0.1653
Other Hispanic	-22.628 (-60.452, 15.197) 0.2581	-15.736 (-48.012, 16.540) 0.3535	0.001 (-0.002, 0.004) 0.5922
Non-Hispanic White	-55.380 (-79.812, -30.948) 0.0004	-45.495 (-69.229, -21.760) 0.0017	-0.001 (-0.004, 0.002) 0.4875

Non-Hispanic Black	-25.300 (-56.338, 5.739) 0.1297	-18.889 (-43.623, 5.845) 0.1539	0.001 (-0.002, 0.004) 0.5838
Other Race	-46.466 (-114.791, 21.860) 0.2012	-26.438 (-80.327, 27.451) 0.3506	0.003 (-0.001, 0.007) 0.2072
P for interaction	0.5184	0.4616	0.411
Poverty to income ratio			
Low	-34.271 (-60.686, -7.856) 0.0210	-27.014 (-50.210, -3.819) 0.0356	0.000 (-0.002, 0.003) 0.7870
Middle	-48.710 (-75.697, -21.724) 0.0025	-34.516 (-60.390, -8.642) 0.0181	0.001 (-0.002, 0.003) 0.5994
High	-54.993 (-80.341, -29.645) 0.0005	-45.157 (-67.337, -22.977) 0.0009	-0.001 (-0.004, 0.002) 0.5327
P for interaction	0.5098	0.5314	0.6318
Education			
Less than high school	-47.846 (-79.581, -16.112) 0.0085	-38.519 (-63.341, -13.697) 0.0070	-0.001 (-0.004, 0.002) 0.5948
High school	-59.084 (-102.370, -15.797) 0.0154	-39.868 (-75.550, -4.185) 0.0419	0.001 (-0.002, 0.004) 0.5016
More than high school	-43.150 (-65.556, -20.744) 0.0014	-35.369 (-55.242, -15.496) 0.0026	-0.000 (-0.003, 0.002) 0.8110
P for interaction	0.8383	0.966	0.532
Marital status			
Married	-61.886 (-81.615, -42.158) <0.0001	-45.675 (-66.876, -24.474) 0.0005	0.000 (-0.003, 0.003) 0.9649
Single	-27.289 (-54.732, 0.153) 0.0670	-23.508 (-44.799, -2.217) 0.0441	-0.000 (-0.002, 0.002) 0.8715
Living with a partner	-44.417 (-101.071, 12.238) 0.1418	-39.595 (-80.389, 1.199) 0.0732	-0.000 (-0.006, 0.005) 0.8982
P for interaction	0.1185	0.2816	0.9857
BMI			
<24	-67.693 (-106.013, -29.374) 0.0030	-56.659 (-97.460, -15.858) 0.0145	-0.001 (-0.005, 0.004) 0.8299
24-28	-43.779 (-80.818, -6.740) 0.0333	-40.181 (-70.351, -10.011) 0.0183	-0.001 (-0.005, 0.002) 0.4905
>=28	-49.169 (-67.223, -31.114) 0.0001	-33.329 (-49.385, -17.272) 0.0008	0.001 (-0.001, 0.003) 0.4058
P for interaction	0.6486	0.4484	0.5656
Physical activity			

Low	-58.944 (-77.183, -40.706)	-42.699 (-61.114, -24.285)	0.001 (-0.002, 0.003)
	<0.0001	0.0003	0.6881
Moderate	-47.312 (-68.558, -26.066)	-37.290 (-57.471, -17.110)	0.000 (-0.003, 0.003)
	0.0004	0.0020	0.9104
High	-30.151 (-61.073, 0.770)	-27.546 (-54.238, -0.853)	-0.001 (-0.004, 0.002)
	0.0720	0.0582	0.4341
P for interaction	0.1605	0.5066	0.6423
Foods of affecting SUA eaten during past 30 days			
Yes	-49.933 (-69.503, -30.362)	-37.399 (-55.697, -19.100)	0.000 (-0.002, 0.002)
	0.0001	0.0008	0.7676
No	-42.106 (-67.458, -16.755)	-35.895 (-58.899, -12.891)	-0.001 (-0.004, 0.002)
	0.0042	0.0065	0.5348
P for interaction	0.627	0.9138	0.4445
Had at least 12 alcohol drinks/1 year			
Yes	-50.300 (-67.638, -32.963)	-38.148 (-55.449, -20.846)	-0.000 (-0.002, 0.002)
	<0.0001	0.0004	0.9478
No	-37.749 (-63.121, -12.378)	-32.549 (-52.836, -12.262)	-0.000 (-0.003, 0.003)
	0.0089	0.0053	0.9752
P for interaction	0.3626	0.6284	0.9953
Smoked at least 100 cigarettes in life			
Yes	-48.298 (-71.894, -24.703)	-39.029 (-61.529, -16.530)	-0.001 (-0.003, 0.002)
	0.0007	0.0030	0.6641
No	-47.072 (-64.976, -29.169)	-35.228 (-50.739, -19.718)	0.000 (-0.002, 0.002)
	0.0001	0.0003	0.7054
P for interaction	0.9282	0.7394	0.5088
Hypertension history			
Yes	-26.397 (-54.816, 2.021)	-25.920 (-53.299, 1.459)	-0.001 (-0.005, 0.003)
	0.0845	0.0791	0.7059
No	-53.375 (-70.485, -36.265)	-39.942 (-55.362, -24.523)	0.000 (-0.002, 0.002)
	<0.0001	0.0001	0.8961
P for interaction	0.0651	0.2693	0.6525
Diabetes history			
Yes	-70.999 (-122.748, -19.251)	-46.636 (-84.581, -8.691)	0.002 (-0.004, 0.009)
	0.0145	0.0263	0.4751
No	-45.819 (-61.471, -30.167)	-36.206 (-51.621, -20.792)	-0.000 (-0.002, 0.002)
	<0.0001	0.0002	0.7894



P for interaction	0.3344	0.5759	0.4088
Respiratory diseases history			
Yes	-63.072 (-101.827, -24.317) 0.0048	-55.249 (-88.176, -22.321) 0.0039	-0.001 (-0.004, 0.002) 0.4959
No	-44.122 (-59.773, -28.471) <0.0001	-32.801 (-47.532, -18.069) 0.0003	0.000 (-0.002, 0.002) 0.8571
P for interaction	0.3404	0.1544	0.4511

Note 1: Above adjusts for gender, age, race/ethnicity, education level, poverty income ratio, marital status, physical activity, BMI, hypertension history, diabetes history, respiratory disease history, had at least 12 alcohol drinks/1 year, smoked at least 100 cigarettes in life, foods of affecting SUA eaten during past 30 days, serum calcium, phosphorus, total bilirubin, total protein, aspartate aminotransferase, alkaline phosphatase, total cholesterol, and glycohemoglobin. Note 2: In each case, the model was not adjusted for the stratification variable itself.

Supplementary Table 3. Multivariate weighted regression model analysis reveals the associations between SUA/SCr and lung function parameters.

	Fully Adjusted Model (With complete data)	Fully Adjusted Model (With missing data)	Fully Adjusted Model (multiple imputation)
	$\beta$ (95% CI) P value	$\beta$ (95% CI) P value	$\beta$ (95% CI) P value
FVC			
SUA/SCr	-47.630 (-63.499, -31.761) <0.0001	-48.003 (-63.362, -32.643) <0.0001	-47.974 (-63.161, -32.787) <0.0001
SUA/SCr quartile categories			
Q1	reference	reference	reference
Q2	-66.127 (-113.530, -18.724) 0.0136	-66.017 (-110.436, -21.598) 0.0121	-65.987 (-110.373, -21.602) 0.0093
Q3	-87.273 (-138.182, -36.365) 0.0035	-89.823 (-138.560, -41.086) 0.0032	-89.320 (-137.966, -40.674) 0.0021
Q4	-123.615 (-172.507, -74.723) 0.0001	-128.144 (-175.740, -80.548) 0.0001	-128.505 (-175.674, -81.337) <0.0001
P for trend	<0.0001	-40.892 (-55.024, -26.760) <0.0001	<0.0001
FEV1			
SUA/SCr	-36.956 (-52.375, -21.537) 0.0001	-37.337 (-52.086, -22.589) 0.0002	-37.346 (-52.023, -22.670) 0.0001
SUA/SCr quartile categories			
Q1	reference	reference	reference
Q2	-54.074 (-93.022, -15.125) 0.0140	-53.905 (-92.170, -15.640) 0.0162	-53.540 (-91.772, -15.308) 0.0133

Q3	-75.024 (-117.771, -32.278) 0.0029	-74.483 (-115.350, -33.616) 0.0034	-74.096 (-115.003, -33.190) 0.0023
Q4	-99.934 (-145.484, -54.384) 0.0004	-104.882 (-149.163, -60.602) 0.0005	-104.937 (-149.224, -60.650) 0.0002
P for trend	0.0002	-33.597 (-47.076, -20.117) 0.0002	0.0001
<hr/>			
FEV1/FVC			
SUA/SCr	-0.000 (-0.002, 0.002) 0.9469	-0.000 (-0.002, 0.002) 0.9708	-0.000 (-0.002, 0.002) 0.9738
SUA/SCr quartile categories			
Q1	reference -0.001 (-0.005, 0.004) 0.7059	reference -0.001 (-0.005, 0.004) 0.7443	reference -0.001 (-0.005, 0.004) 0.7721
Q2	-0.001 (-0.006, 0.004) 0.7037	-0.001 (-0.005, 0.004) 0.8249	-0.001 (-0.005, 0.004) 0.8241
Q3	-0.001 (-0.006, 0.005) 0.7503	-0.001 (-0.006, 0.004) 0.7000	-0.001 (-0.006, 0.004) 0.7224
Q4		-0.000 (-0.002, 0.001) 0.7387	0.7517
P for trend	0.7492		

Note 1: Non-adjusted model adjusted for none. Note 2: Minimally adjusted model adjusts for gender, age, and race/ethnicity. Note 3: Fully adjusted model adjusts for gender, age, race/ethnicity, education level, poverty income ratio, marital status, physical activity, BMI, hypertension history, diabetes history, respiratory disease history, had at least 12 alcohol drinks/1 year, smoked at least 100 cigarettes in life, foods of affecting SUA eaten during past 30 days, serum calcium, phosphorus, total bilirubin, total protein, aspartate aminotransferase, alkaline phosphatase, total cholesterol and glycohemoglobin.